Carregant...
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy. First‐ and second‐generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156184/ https://ncbi.nlm.nih.gov/pubmed/29650685 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0582 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|